- FAST III was initiated five years ago to evaluate whether revascularization guided by angiography-based FFR using CAAS vFFR (vessel Fractional Flow Reserve) delivers therapeutic outcomes comparable to those achieved with pressure wire-based FFR.
- Positive non-inferior result validates angiography-based vFFR as a safe and effective alternative for guiding revascularization
- Paves the way for reimbursement of less invasive testing for patients with intermediate coronary stenoses
- FAST III is a study sponsored by the European Cardiovascular Research Institute, supported by research grants from industry partners Siemens Healthineers and Pie Medical Imaging.
MAASTRICHT, Netherlands, March 29, 2026 /PRNewswire/ -- Pie Medical Imaging, a global leader in cardiac imaging analysis Solutions announces the result of the FAST III trial, presented during the Late-Breaking Clinical Trials session at the Congress of the American College of Cardiology (ACC) 2026 and published in the New England Journal of Medicine. The trial confirms non-inferiority of revascularization guided by CAAS vFFR to revascularization guided by pressure wire-based FFR.
Photo - https://mma.prnewswire.com/media/2943619/FAST_III_PR_Image.jpg
Logo - https://mma.prnewswire.com/media/2438117/PMI_logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fast-iii-trial-demonstrates-non-inferiority-of-caas-vffr-to-invasive-wire-based-ffr-302727552.html
